Considering the significantly elevated expression levels of GLP-1R in diabetic patients, it is hypothesized that administration of GLP-1R agonists may elevate the risk of breast cancer progression in these patients, thus necessitating particular caution in clinical management [101]. The gene discussed is GLP1R; the disease is breast cancer.